Detalles de la búsqueda
1.
Antiglioma activity of GoPI-sugar, a novel gold(I)-phosphole inhibitor: chemical synthesis, mechanistic studies, and effectiveness in vivo.
Biochim Biophys Acta
; 1844(8): 1415-26, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24440405
2.
Investigations on the use of fluorescence dyes for labeling dendrimers: cytotoxicity, accumulation kinetics, and intracellular distribution.
Bioconjug Chem
; 21(12): 2222-6, 2010 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21049938
3.
Current trends in multiple myeloma management.
J Int Med Res
; 36(3): 371-86, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18534118
4.
Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.
J Int Med Res
; 36(3): 400-13, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18534121
5.
Organometallic gold(iii) complexes with hybrid SNS-donating thiosemicarbazone ligands: cytotoxicity and anti-Trypanosoma cruzi activity.
Dalton Trans
; 46(8): 2559-2571, 2017 Feb 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-28154849
6.
Paclitaxel-loaded microparticles and implants for the treatment of brain cancer: preparation and physicochemical characterization.
Int J Pharm
; 314(2): 127-36, 2006 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-16490330
7.
Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
Eur J Med Chem
; 124: 49-62, 2016 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-27560282
8.
[Characterization of an experimental venous thrombus model with MRI, phlebography and histology]. / Charakterisierung eines experimentellen venösen Thrombosemodells mittels MRT, Phlebographie und Histologie.
Rofo
; 177(3): 411-9, 2005 Mar.
Artículo
en Alemán
| MEDLINE | ID: mdl-15719305
9.
Investigation of the configurational and conformational influences on the hormonal activity of 1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamines and of their platinum(II) complexes. 1. Synthesis, estradiol receptor affinity, and estrogenic activity of diastereomeric [N-alkyl- and N,N'-dialkyl-1,2- bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes.
J Med Chem
; 38(12): 2070-9, 1995 Jun 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-7783138
10.
Investigations of new lead structures for the design of selective estrogen receptor modulators.
J Med Chem
; 44(12): 1963-70, 2001 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-11384241
11.
Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2- phenylethylenediamine](sulfato)platinum-(II) complexes with variable substituents in the 2-phenyl ring. 1. Synthesis and antitumor and estrogenic properties.
J Med Chem
; 33(9): 2535-44, 1990 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-2391694
12.
Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma.
J Med Chem
; 31(1): 72-83, 1988 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-3336035
13.
Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits.
Invest Radiol
; 35(8): 460-71, 2000 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-10946973
14.
Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls.
Invest Radiol
; 37(7): 405-11, 2002 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12068163
15.
[Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
J Cancer Res Clin Oncol
; 126(11): 647-54, 2000 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-11079729
16.
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
J Cancer Res Clin Oncol
; 124(11): 585-97, 1998.
Artículo
en Inglés
| MEDLINE | ID: mdl-9860287
17.
[meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II), a new drug not only parenterally but also orally active in the therapy of breast and prostate cancer.
J Cancer Res Clin Oncol
; 119(12): 707-16, 1993.
Artículo
en Inglés
| MEDLINE | ID: mdl-8408183
18.
Influence of ring substituents on the antitumor effect of dichloro(1,2-diphenylethylenediamine)platinum(II) complexes.
J Cancer Res Clin Oncol
; 114(4): 347-58, 1988.
Artículo
en Inglés
| MEDLINE | ID: mdl-3410875
19.
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.
J Cancer Res Clin Oncol
; 118(3): 201-8, 1992.
Artículo
en Inglés
| MEDLINE | ID: mdl-1548285
20.
[1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. III. Detailed evaluation of the antitumor activity of the enantiomeric complexes on the human NIH:OVCAR-3 ovarian cancer cell line.
J Cancer Res Clin Oncol
; 118(3): 209-15, 1992.
Artículo
en Inglés
| MEDLINE | ID: mdl-1548286